Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents [PDF]
Pharmacogenomics and Personalized Medicine, 2016 Adem Yesuf Dawed, Kaixin Zhou, Ewan Robert Pearson Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, Scotland, UK Abstract: Type 2 diabetes is one of the leading causes of morbidity ...
Dawed AY, Zhou K, Pearson ER
doaj +5 more sources
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2017 The Korean Diabetes Association (KDA) recently updated the Clinical Practice Guidelines on antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus (T2DM).
Min Kyong Moon +10 more
doaj +5 more sources
Comparative evaluation of biphasic insulin with metformin and triple oral hypoglycemic agents (OHA) in type 2 diabetes patients [PDF]
Saudi Pharmaceutical Journal, 2020 Introduction: The prevalence of secondary failure to oral hypoglycemic agents among type 2 diabetes mellitus (T2DM) patients ranges from 30 to 60%. The alternative approaches to overcome this issue are either switching to triple oral hypoglycemic agents (
Sirajudeen Shaik Alavudeen +6 more
doaj +3 more sources
Oral Hypoglycemic Agents in pregnancy: An Update. [PDF]
J Obstet Gynaecol India, 2013 Traditionally, insulin has been the gold standard in the management of Type 2 diabetes in pregnancy and gestational diabetes. However, insulin therapy can be inconvenient because of the needs for multiple injections, its associated cost, pain at the injection site, need for refrigeration, and skillful handling of the syringes.
Kavitha N, De S, Kanagasabai S.
europepmc +6 more sources
Primary Care: Clinics in Office Practice, 1977 Oral agents should not be used in the treatment of patients with asymptomatic maturity-onset diabetes. The indication for sulfonylureas is symptomatic maturity-onset diabetes or excessive hyperglycemia--fasting blood sugar over 300 mg per 100 ml--in the elderly patient who cannot or will not take insulin. The use of biguanides cannot be recommended.
Harold Rifkin
semanticscholar +9 more sources
Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression: A retrospective cohort study. [PDF]
Pharmacol Res Perspect, 2019 Type 2 diabetes mellitus (T2DM) is a risk factor for depression. Since brain insulin resistance plays a potential role in depression, the future risk of depression in patients with T2DM may be altered depending on the class of oral hypoglycemic agent ...
Akimoto H +5 more
europepmc +2 more sources
Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy. [PDF]
J Diabetes Res, 2018 The purpose of this study was to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. The medical records of 21 type 2 diabetic patients who used a
Cho EH +5 more
europepmc +2 more sources
Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database. [PDF]
J Diabetes Investig, 2017 In treatment algorithms of type 2 diabetes mellitus in Western countries, biguanides are recommended as first‐line agents. In Japan, various oral hypoglycemic agents (OHAs) are available, but prescription patterns are unclear.
Tanabe M +4 more
europepmc +2 more sources
Gestational diabetes mellitus management with oral hypoglycemic agents. [PDF]
Semin Perinatol, 2014 Oral hypoglycemic agents such as glyburide (second-generation sulfonylurea) and metformin (biguanide) are attractive alternatives to insulin due to lower cost, ease of administration, and better patient adherence.
Ryu RJ, Hays KE, Hebert MF.
europepmc +2 more sources
Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in Korea. [PDF]
J Diabetes Investig, 2017 To assess the time to initiation of insulin therapy, and concurrently investigate both patient‐ and physician‐related factors associated with delaying insulin therapy in Korean patients with type 2 diabetes uncontrolled by oral hypoglycemic agents (OHAs).
Kim SG +8 more
europepmc +2 more sources